This result builds upon the findings of Taylor et al. who observed that amplifications of the Wnt/β-catenin pathway modulators MED12 and MED12L were also more common among BRCA2 PSV carriers and that BRCA2d prostate cancers have been shown to experience global hypomethylation relative to sporadic cancers7. This evidence concerns the gene BRCA2 and prostate carcinoma.